Comparison · NCT01662908-4cf3edd7
Edoxaban vs Warfarin: Number of Participants With Major Adverse Cardiovascular Events (MACE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Edoxaban vs Warfarin: Number of Participants With Major Adverse Cardiovascular Events (MACE). Trial comparisons, record NCT01662908-4cf3edd7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01662908-4cf3edd7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0357 | 0.00985 | 0.121 | wilson | |
| Risk in group 2 | 0 | 0.0000000000000000139 | 0.121 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0357 | -0.0877 | 0.121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Edoxaban than on Warfarin | 28 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Edoxaban | Participants treated with edoxaban | 2 | 56 | OG000 |
| Group 2 | Warfarin | Participants treated with warfarin | 0 | 28 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Major Adverse Cardiovascular Events (MACE)
- Description
- MACE is defined as a composite of non-fatal myocardial infarction (MI), non-fatal stroke, non-fatal systemic embolic event (SEE) and cardiovascular death
- Time frame
- Initial dose of study drug up to 3 days after last dose
- Population
- Adjudicated confirmed events in the mITT population
Source ClinicalTrials.gov
Trial
- Title
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
- NCT number
- NCT01662908
- Phases
- PHASE2
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis
- Interventions
- edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin
- Lead sponsor
- Daiichi Sankyo
- Results first posted
- 2017-05-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01662908?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01662908-4cf3edd7